(alphaS)-alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-环己烷丙酸甲酯 | 98105-41-0

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (alphaS)-alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-环己烷丙酸甲酯
• 中文别名: 叔丁氧羰基-3-环己基-L-丙氨酸甲酯；Boc-3-环己基-L-丙氨酸甲基酯
• 英文名称: methyl S-3-cyclohexyl-2-(t-butoxycarbonylamino)propionate
• 英文别名: (2S)-2-tert-butoxycarbonylamino-3-cyclohexylpropanoic acid methyl ester；N-Boc-L-cyclohexylalanine methyl ester；L-Boc-cyclohexylalanine methyl ester；Boc-cyclohexylalanine methyl ester；N-t-butyloxycarbonyl-3-cyclohexyl-L-alanine methyl ester；Boc-3-cyclohexyl-L-alanine methyl ester；methyl (2S)-3-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 98105-41-0
• 化学式: C₁₅H₂₇NO₄
• 分子量: 285.384
• InChiKey: FALUXMVPGFKLAM-LBPRGKRZSA-N

物化性质

• 熔点：
  47-49 °C(lit.)
• 沸点：
  386.9±25.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，没有已知的危险反应。应避免与强氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将贮藏器保持密封，并存放在阴凉、干燥处。同时，确保工作环境具有良好的通风或排气设施。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Boc-Cha-OMe
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 98105-41-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : Boc-3-cyclohexyl-L-alanine methyl ester
N-(tert-Butoxycarbonyl)-3-cyclohexyl-L-alanine methyl ester
Formula : C15H27NO4
Molecular Weight : 285,38 g/mol
CAS-No. : 98105-41-0
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 47 - 49 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

BocChaOME是一种丙氨酸衍生物。

反应信息

• 作为反应物：
  描述：

  (alphaS)-alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-环己烷丙酸甲酯 在 甲醇 、 二异丁基氢化铝 作用下， 以 正己烷 、 甲苯 为溶剂， 反应 2.0h， 以80%的产率得到2-甲基-2-丙基[(2S)-1-环己基-3-氧代-2-丙基]氨基甲酸酯
  参考文献：
  名称：

  肾素抑制剂。包含新的他汀类药物类似物的亚纳摩尔竞争性过渡态类似物抑制剂的合成。

  摘要：

  合成了肾素八肽底物的类似物，其中用（3S，4S）-4-氨基-3-羟基-6-甲基庚酸（statine，Sta）取代易裂二肽将底物序列转变为有效的过渡态类似物，肾素的竞争性抑制剂。Sta的环己基丙氨酰基类似物（3S，4S）-4-氨基-5-环己基-3-羟基戊酸（ACHPA）的合成和掺入提供了迄今为止报道的最有效的肾素抑制剂，包括N-异戊基-L-组氨酸-L-脯氨酰基-L-苯丙氨酰基-L-组氨酸-ACHPA-L-亮氨酰-L-苯丙氨酰胺[Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2,3]，肾素抑制Ki = 1.6 X 10（-10）M（人肾素），IC50 = 1.7 X 10（-10）M（人血浆肾素），IC50 = 1.9 X 10（-9）M（犬血浆肾素）和IC50 = 2.1 X 10（-8）M（大鼠血浆肾素）。含有ACHPA的这种抑制剂3，与人肾素的效价比含Sta的抑

  DOI：

  10.1021/jm00150a007
• 作为产物：
  描述：

  2-环己烯醇 在 palladium on activated charcoal 吡啶 、 三甲基氯硅烷 、 氢气 、 锌 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.41h， 生成 (alphaS)-alpha-[[(1,1-二甲基乙氧基)羰基]氨基]-环己烷丙酸甲酯
  参考文献：
  名称：

  使用丝氨酸衍生的有机锌试剂制备β-环烷基丙氨酸衍生物的新途径。

  摘要：

  已经开发出两种不同的制备β-环烷基丙氨酸衍生物的途径。第一种方法使用碘代丙氨酸衍生的锌-铜试剂2与环烷-1-烯-3-基磷酸酯的反应，第二种方法使用钯催化的碘代丙氨酸衍生的锌试剂1与环烯基三氟甲磺酸酯的偶联。在每种情况下，不饱和产物的催化加氢产生被保护的β-环烷基丙氨酸。后一种途径允许获得范围为5-8的环烷基的一系列环烷基衍生物。可以使用锌-铜试剂2与3-甲基-2-环己烯基氯的反应，然后氢化来制备β-（1-甲基-1-环己基）丙氨酸。相应的环戊基衍生物可通过将相同的锌铜试剂2与二乙基香叶基磷酸酯反应制得，

  DOI：

  10.1039/b512784j

文献信息

• Synthesis of 2-isoxazoline and α-hydroxy ketomethylene dipeptide isosteres
  作者：Yong Jun Chung、Eun Jung Ryu、Gyochang Keum、Kim Byeang Hyean

  DOI：10.1016/0968-0896(95)00174-3

  日期：1996.2

  We have developed a simple and stereoselective method for synthesizing novel dipeptide isosteres using nitrile oxide cycloaddition as a key reaction. Employing this method, we have prepared efficiently various peptidomimetics containing 2-isoxazolines and alpha-hydroxy ketomethylene dipeptide isosteres.

  我们已经开发了一种简单且立体选择性的方法，用于使用一氧化氮环加成作为关键反应来合成新型二肽等位基因。利用这种方法，我们有效地制备了各种含有2-异恶唑啉和α-羟基酮亚甲基二肽等排体的拟肽。
• Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency
  作者：Jay R. Luly、Nwe BaMaung、Jeff Soderquist、Anthony K. L. Fung、Herman Stein、Hollis D. Kleinert、Patrick A. Marcotte、David A. Egan、Barbara Bopp

  DOI：10.1021/jm00120a005

  日期：1988.12

  extremely selective for human renin over the related enzymes cathepsin D, pepsin, and gastricsin. At high concentrations, compounds containing a leucine or phenylalanine rather than a histidine at the P2 position gave only minor amounts of inhibition of the other enzymes. Inhibitor 43 suppressed plasma renin activity completely and lowered mean blood pressure in monkeys after both intravenous and intraduodenal

  含二醇的肾素抑制剂的合成表明，与人血管紧张素原中易裂的Leu-Val键相对应的简单邻位二醇官能团能够以与相应的醛或羟甲基官能团相当或更高的水平赋予抑制活性（比较抑制剂2a-c或3a-c）。这一发现通过在Leu-Val替代物中包含第二个羟基，从而在200-700-pM范围内抑制人肾素的化合物（例如43）进一步优化了一系列小型过渡态类似物抑制剂。 ，45，63，66）。第二羟基对效能的影响大小不仅由二醇的绝对立体化学决定，而且由P1残基的侧链决定。含二醇抑制剂的分子模型表明，一个羟基氢键与Asp 32和Asp 215，而另一个氢键与Asp215。这些二醇抑制剂对人肾素的选择性超过相关的组织蛋白酶D，胃蛋白酶和胃蛋白酶。在高浓度下，在P2位上含有亮氨酸或苯丙氨酸而不是组氨酸的化合物对其他酶的抑制作用很小。在静脉内和十二指肠内给药后，抑制剂43完全抑制了血浆血浆肾素活性，并降低了猴子的平均血压，但
• N-t-butyloxycarbonyl-3-cyclohexyl-L-alanine methyl ester in crystalline
  申请人：Ajinomoto Co., Inc.

  公开号：US05286897A1

  公开（公告）日：1994-02-15

  N-t-butyloxycarbonyl-3-cyclohexyl-L-alanine methyl ester, previously known only as an oil, is provided in crystalline form. By addition of an organic solvent, such as methanol and/or n-hexane, to the ester in the form of an oil and cooling, crystals may be obtained. Alternatively, the ester in oily form may be seeded with a crystal produced previously. The crystalline material is of higher purity than the previously known oils, and is more useful than the oils as an intermediate in the pharmaceutical industry.

  N-叔丁氧羰基-3-环己基-L-丙氨酸甲酯，以前只以油的形式存在，现以结晶形式提供。通过向油状酯中添加有机溶剂，如甲醇和/或正己烷，并冷却，可以得到结晶体。或者，可用之前产生的晶体来催化油状酯。这种结晶材料比以前已知的油更纯，作为制药工业中间体比油更有用。
• Reductions of Aromatic Amino Acids and Derivatives
  作者：David J. Ager、Indra Prakash

  DOI：10.1021/op0200773

  日期：2003.3.1

  Catalytic reduction of phenylalanine and phenylglycine derivatives can be achieved with rhodium on carbon or alumina to give good yields of the corresponding cyclohexyl derivatives. The procedure can be scaled.

  苯丙氨酸和苯甘氨酸衍生物的催化还原可以用碳或氧化铝上的铑来实现，从而得到相应的环己基衍生物的良好收率。该过程可以缩放。
• CHEMICALLY AMPLIFIED RESIST MATERIAL, PATTERN-FORMING METHOD, COMPOUND, AND PRODUCTION METHOD OF COMPOUND
  申请人：OSAKA UNIVERSITY

  公开号：US20170052449A1

  公开（公告）日：2017-02-23

  A pattern-forming method comprises patternwise exposing a predetermined region of a resist material film made from a photosensitive resin composition comprising a chemically amplified resist material to a first radioactive ray that is ionizing radiation or nonionizing radiation having a wavelength of no greater than 400 nm. The resist material film patternwise exposed is floodwise exposed to a second radioactive ray that is nonionizing radiation having a wavelength greater than the wavelength of the nonionizing radiation for the patternwise exposing and greater than 200 nm. The chemically amplified resist material comprises a base component, and a generative component that is capable of generating a radiation-sensitive sensitizer and an acid upon an exposure. The generative component comprises a radiation-sensitive sensitizer generating agent. The radiation-sensitive sensitizer generating agent comprises a compound represented by formula (A).

  一种图案形成方法包括将一种化学放大型光刻胶材料制成的感光树脂组成物的预定区域图案暴露于第一种放射性射线中，该放射性射线是电离辐射或波长不大于400 nm的非电离辐射。图案化暴露的光刻胶材料膜被洪水式暴露于第二种放射性射线中，该放射性射线是波长大于图案化暴露的非电离辐射的波长和大于200 nm的非电离辐射。该化学放大型光刻胶材料包括基础组分和能够在暴露时生成辐射敏感的敏化剂和酸的生成组分。生成组分包括辐射敏感的敏化剂生成剂。辐射敏感的敏化剂生成剂包括由式(A)表示的化合物。